Tweet
Trends Biotechnol. 2019 Dec 3. pii: S0167-7799(19)30241-0. doi: 10.1016/j.tibtech.2019.09.009. [Epub ahead of print] Next-Generation Sequencing: An Eye-Opener for the Surveillance of Antiviral Resistance in Influenza.
Van Poelvoorde LAE1, Saelens X2, Thomas I3, Roosens NH4.
Author information
1 Transversal Activities in Applied Genomics, Sciensano, Juliette Wytsmansstraat 14, 1050 Brussels, Belgium; National Influenza Centre, Sciensano, Juliette Wytsmansstraat 14, 1050 Brussels, Belgium; Department of Biochemistry and Microbiology, Ghent University, Technologiepark-Zwijnaarde 71, 9052 Ghent, Belgium; VIB-UGent Center for Medical Biotechnology, Technologiepark-Zwijnaarde 71, 9052 Ghent, Belgium. 2 Department of Biochemistry and Microbiology, Ghent University, Technologiepark-Zwijnaarde 71, 9052 Ghent, Belgium; VIB-UGent Center for Medical Biotechnology, Technologiepark-Zwijnaarde 71, 9052 Ghent, Belgium. 3 National Influenza Centre, Sciensano, Juliette Wytsmansstraat 14, 1050 Brussels, Belgium. 4 Transversal Activities in Applied Genomics, Sciensano, Juliette Wytsmansstraat 14, 1050 Brussels, Belgium. Electronic address: nancy.roosens@sciensano.be.
Abstract
Next-generation sequencing (NGS) can enable a more effective response to a wide range of communicable disease threats, such as influenza, which is one of the leading causes of human morbidity and mortality worldwide. After vaccination, antivirals are the second line of defense against influenza. The use of currently available antivirals can lead to antiviral resistance mutations in the entire influenza genome. Therefore, the methods to detect these mutations should be developed and implemented. In this Opinion, we assess how NGS could be implemented to detect drug resistance mutations in clinical influenza virus isolates.
Copyright ? 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.
KEYWORDS:
antiviral resistance; influenza; next-generation sequencing; surveillance
PMID: 31810633 DOI: 10.1016/j.tibtech.2019.09.009
Free full text